Yes. Some weight-loss medicines may improve obstructive sleep apnea by helping people lose weight, and tirzepatide (Zepbound) is approved in the United States for adults with obesity and moderate-to-severe obstructive sleep apnea. It is used with a reduced-calorie eating plan and physical activity. These medicines do not work for everyone, and they are not a reason to stop CPAP or another sleep-apnea treatment without reassessment.
How can weight loss medication affect sleep apnea?
Obstructive sleep apnea (OSA) occurs when the upper airway becomes partly or completely blocked during sleep, causing breathing to become shallow or stop briefly. Excess body fat can contribute to this problem, particularly when fatty tissue around the neck narrows the airway. According to the National Heart, Lung, and Blood Institute (NHLBI), maintaining a healthy weight can help prevent or treat sleep apnea associated with obesity.
Weight-loss medicines can help eligible people reduce body weight by changing appetite, food intake, or other processes involved in weight management. When treatment leads to meaningful weight loss, it may also reduce the number of breathing interruptions that occur during sleep. However, sleep apnea has several possible contributing factors, including the structure of the jaw, tongue, and upper airway. Losing weight therefore does not guarantee that the condition will disappear.
Which weight-loss medication is approved for sleep apnea?
Tirzepatide, sold as Zepbound in the United States, is a prescription medicine that acts on two hormone pathways involved in appetite and food intake: GLP-1 and GIP. On December 20, 2024, the U.S. Food and Drug Administration (FDA) approved Zepbound for treating moderate-to-severe obstructive sleep apnea in adults with obesity, alongside a reduced-calorie diet and increased physical activity.
This approval is specific to the medicine, patient group, and condition described in the FDA's decision. It does not mean that every weight-loss injection, appetite suppressant, or obesity medicine has been proven to treat sleep apnea. Brand names, approved uses, and availability can also differ between countries.
What does the research say about tirzepatide and sleep apnea?
The evidence supporting tirzepatide includes the SURMOUNT-OSA clinical trials, published in the New England Journal of Medicine. The researchers conducted two randomized, placebo-controlled studies involving 469 adults with obesity and moderate-to-severe obstructive sleep apnea who did not have type 2 diabetes. One study included participants who were not using positive airway pressure therapy, while the other included participants already using it.
Over 52 weeks, participants receiving tirzepatide experienced greater reductions in breathing interruptions during sleep and body weight than those receiving a placebo. A larger proportion of participants taking tirzepatide also reached outcomes consistent with remission or mild sleep apnea accompanied by symptom improvement. These findings support a treatment benefit, but they do not establish that everyone taking the medicine will be free of sleep apnea.
The 2026 joint guidance statement from The Obesity Society, the Obesity Medicine Association, and the Obesity Action Coalition also discusses evidence for GLP-1-based medicines in adults with obesity and sleep apnea. The evidence base is evolving, and the benefit expected from one medicine should not automatically be applied to another.
Does weight-loss medication replace CPAP?
No. Starting a weight-loss medicine does not automatically replace continuous positive airway pressure (CPAP), which uses gentle air pressure to help keep the airway open during sleep. The NHLBI's sleep apnea treatment guidance identifies positive airway pressure as the most common treatment and notes that it can be combined with healthy lifestyle changes.
In the SURMOUNT-OSA research, tirzepatide showed benefits in participants both with and without positive airway pressure therapy. This supports considering weight management alongside existing care when appropriate. It does not establish that people using CPAP can safely discontinue it simply because they have lost weight or started an injection.
If weight loss improves snoring, daytime tiredness, or other sleep-related problems, a healthcare professional may recommend reassessing sleep apnea. A repeat sleep study may be needed to determine whether the condition has improved enough to change treatment. Until that decision is made, prescribed CPAP or another established treatment should be continued as directed.
Can other weight-loss medicines improve sleep apnea?
Some other obesity medicines have been studied for their effects on obstructive sleep apnea. For example, research has examined liraglutide and phentermine-topiramate, including changes in body weight and the number of breathing disturbances during sleep. However, evidence varies by medicine, and a medicine approved for weight management is not necessarily approved specifically for sleep apnea.
The practical distinction is between treating excess weight and treating sleep apnea itself. A medicine may help with both, but the expected benefit depends on the medicine, the amount of weight lost, and the factors contributing to the airway obstruction. A prescriber can review the evidence and determine whether a particular treatment is suitable for someone's weight-management needs and sleep-apnea care.
Who might benefit from discussing medication with a healthcare professional?
Adults with obesity and diagnosed obstructive sleep apnea may wish to discuss weight-management treatment when excess weight is part of their health concerns. A clinician can consider existing sleep-study results, current treatments, medical history, other medicines, and any previous attempts at weight management before recommending an approach.
Weight-loss medication is not suitable for everyone. For example, tirzepatide has important prescribing restrictions and warnings, including that it should not be used by people with a personal or family history of medullary thyroid carcinoma or by those with multiple endocrine neoplasia syndrome type 2. Its potential benefits should be weighed against its risks and the person's overall health needs.
What side effects and precautions should you know about?
According to the FDA, common side effects reported with Zepbound include nausea, diarrhea, vomiting, constipation, abdominal discomfort or pain, fatigue, and injection-site reactions. The medicine also carries warnings about potentially serious problems, including inflammation of the pancreas and gallbladder disease. A prescriber should review the official prescribing information and the person's medical history before treatment begins.
Anyone using weight-loss medication should report troublesome or persistent side effects rather than changing the dose independently. Other medicines, existing medical conditions, and planned procedures may affect treatment decisions. A healthcare professional can explain what to monitor and when treatment needs to be reviewed.
How will a clinician know whether the medication is helping?
Changes in weight, snoring, or daytime alertness can be useful to report, but they do not reliably show how often breathing stops during sleep. Clinicians may use a sleep study and its apnea-hypopnea index (AHI), which measures the number of breathing interruptions per hour, to assess changes in obstructive sleep apnea.
Follow-up should consider both the response to weight-management treatment and whether sleep apnea remains adequately controlled. If symptoms persist, worsen, or continue to disrupt daily life, the care plan may need reassessment even when weight has decreased. The aim is to manage weight and maintain effective breathing during sleep rather than relying on weight change alone.
Key takeaways
Weight-loss medication can improve obstructive sleep apnea in some adults, particularly when excess body weight contributes to airway obstruction. Tirzepatide has specific FDA approval in the United States for adults with obesity and moderate-to-severe obstructive sleep apnea, supported by clinical trials. Other medicines may have relevant evidence, but their effects and approved uses differ. Medication should be selected with a healthcare professional, and changes to CPAP or other sleep-apnea treatments should be based on clinical reassessment rather than weight loss alone.